

PROTOCOL CHECKLIST
FOR CONTINUING REVIEWS

- _____ PROTOCOL NUMBER
- _____ NIH-1195-1 (V.9-06) with ALL ITEMS CHECKED and signatures down through and including the Clinical Director
- _____ CLEARANCE OF NIH INVESTIGATOR PERSONAL FINANCIAL HOLDINGS BY IC ETHICS OFFICE (PFH) Version 3/18/08 (WITH DEC APPROVAL) (MANDATORY)
- _____ DESIGNATION OF REIMBURSEMENT FOR TRAVEL AND SUBSISTENCE (DRTS) FORM (MANDATORY)
- _____ COPY OF THE PRECIS/PROTOCOL
- _____ COPY OF PREVIOUS YEAR'S 1195-1 OR 1195
- _____ MEMORANDUM OF PROGRESS CONTAINING THESE ELEMENTS (All elements must be addressed— state n/a if they do not apply)
- _____ 1) Description of study progress;
 - _____ 2) List of amendments over previous year,
 - _____ 3) Past year subject accrual demographics;
 - _____ 4) Detailed cumulative information on previously enrolled subjects (e.g.. status of their current treatment on protocol, current illness status, cure rate, mortality);
 - _____ 5) Explanation of pediatric experience, if any
 - _____ 6) Discussion of any new information that may affect risk or benefit to subjects;
 - _____ 7) Additions or removal of investigators from study (including off-site);
 - _____ 8) The scientific justification for continuation of the protocol based upon the cumulative results of treatment thus far, including specific endpoints of the study;
 - _____ 9) Summary of adverse events as defined in the protocol and approved by the IRB.
 - _____ 10) Data and safety monitoring plan.
 - _____ 11) Study plans.
- _____ Completed Gender Minority Accrual Chart (PHS 398/2590 revised 5/01) **REQUIRED**
- _____ Completed Targeted/ Planned Enrollment Table: Gender Minority Accrual Chart (PHS 398/2590 revised 5/01) Required for Clinical Trials Phase 3 or 4 protocols only
- _____ Completed NIEHS IRB Accrual Data Recruitment Report (Version 9/2004) **REQUIRED**
- _____ List Of Relevant Publications Or Abstracts.
- _____ Current Consents (MANDATORY)
- _____ Current Protocol with all changes since last IRB review noted
- _____ If study involves an IND or IDE, please submit a summary of the FDA annual report.
- _____ Current Off-site IRB Approval (Only for protocols with off-site locations.)
- _____ List of persons authorized to obtain consent if other than the PI or AI is attached; OR
_____ Only principle investigators or associate investigators may obtain consent for this study
- _____ CORRESPONDENCE WITH PI